Jim Simons acquired 6.27M Corcept Therapeutics shares worth $435M. That's 0.55% of their equity portfolio (19th largest holding). The investor owns 5.92% of the outstanding Corcept Therapeutics stock. The first Corcept Therapeutics trade was made in Q1 2015. Since then Jim Simons bought shares 23 more times and sold shares on eighteen occasions. The stake costed the investor $87.2M, netting the investor a gain of 398% so far.